109179 ⎘
Structure or type of the nucleic acid; Chemical structure of the base Modified A
INTERFERING RNA FOR INHIBITING JAK1 GENE EXPRESSION AND USE THEREOF
#2PLIN1 RNAi INTERFERENCE AGENTS
#3COMPOSITIONS AND METHODS FOR DELIVERING A MACROMOLECULE TO A CELL
#4ANTI-FIBROTIC MICRORNA COMPOSITION
#5DOUBLE-STRANDED RNAI AGENTS AND COMPOSITIONS FOR REDUCING EXPRESSION OF ANGIOPOIETIN-LIKE 3 (ANGPTL3) AND METHODS OF USE THEREOF
#6RNA NANOSTRUCTURES WITH BASE MODIFICATIONS FOR REDUCING INNATE IMMUNOGENICITY
#7ADVANCED RNA TARGETING (ARNATAR)
#8NUCLEOTIDE ANALOGUES, AND PREPARATION AND APPLICATION THEREOF
#9RNAI AGENT INHIBITING PCSK9 GENE EXPRESSION AND APPLICATION THEREOF
#10APTAMER, CONJUGATE, COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF
#11PRODUCTS AND COMPOSITIONS
#12ENHANCED HAMMERHEAD RIBOZYMES AND METHODS OF USE
#13POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
#14EXPONENTIAL BASE-3 AND GREATER NUCLEIC ACID AMPLIFICATION WITH REDUCED AMPLIFICATION TIME
#15INHIBIN SUBUNIT BETA E INHIBITOR AND METHODS OF USE THEREOF
#16COMPOSITIONS AND METHODS FOR PREPARING CAPPED CIRCULAR RNA MOLECULES
#17METHODS AND SYSTEMS TO MINIMIZE BARCODE EXCHANGE
#18GUIDE RNA WITH CHEMICAL MODIFICATIONS
#19Application of PRDX5 and GPX4 Genes in Preparation of Drugs for Castration-resistant Prostate Cancer
#20RNA MODULATING OLIGONUCLEOTIDES WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
#21Nucleic Acid Sponges
#22SNRNA TARGETING USH2A PRE-MRNA AND APPLICATION THEREOF
#23Therapeutic Editing
#24GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT
#25ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE
#26Oligonucleotide Comprising Inosine for Treating DMD
#27MODIFIED OLIGONUCLEOTIDES
#28RNA PREPARATIONS COMPRISING PURIFIED MODIFIED RNA FOR REPROGRAMMING CELLS
#29GUIDE RNA WITH CHEMICAL MODIFICATIONS
#30MODIFIED FUNCTIONAL NUCLEIC ACID MOLECULES
#31METHOD FOR TREATING AND PROGNOSING CANCER LIKE GLIOBLASTOMA
#32Exponential base-3 and greater nucleic acid amplification with reduced amplification time
#33Methods and compositions for modulating splicing
#34Therapeutic editing
#35METHODS AND COMPOSITIONS FOR MODULATING SPLICING
#36IMMUNOSTIMULATORY SEQUENCE OLIGONUCLEOTIDES AND METHODS OF USING THE SAME
#37RNA INTERFERENCE-INDUCING NUCLEIC ACID INHIBITING NONCANONICAL TARGETS OF MICRO RNA, AND USE FOR SAME
#38Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
#39Method for generating aptamers with improved off-rates
#40RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of Use
#41ISOLATION OF TARGET NUCLEIC ACIDS
#42Compositions and methods for Editing Nucleic Acids in Cells Utilizing Oligonucleotides
#43HIF 1-alpha antisense oligonucleotides
#44Compositions and methods for evading bacterial defense mechanisms
#45Oligonucleotide comprising an inosine for treating DMD
#46S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS
#47GUIDE RNA WITH CHEMICAL MODIFICATIONS
#48Read through of truncated proteins in premature termination codon diseases using an optimized genetic codon expansion system
#49Genome editing using effector oligonucleotides for therapeutic treatment
#50RNAi agents for inhibiting expression of alpha-ENaC and methods of use
#51Oligonucleotide comprising an inosine for treating DMD
#52Methods and compositions for modulating splicing
#53Methods and systems to minimize barcode exchange
#54Methods and compositions for modulating splicing
#55Exponential base-3 and greater nucleic acid amplification with reduced amplification time
#56Methods and compositions for modulating splicing
#57Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
#58Methods of enhancing translation ability of RNA molecules, treatments, and kits
#59RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
#60CHIMERIC RNA OLIGONUCLEOTIDES AND USES THEREOF
#61SCN9A antisense pain killer
#62Method for generating aptamers with improved off-rates
#63ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES
#64Immunostimulatory sequence oligonucleotides and methods of using the same
#65Method for Generating Aptamers with Improved Off-Rates
#66Engineered guide RNA and uses thereof
#67Secretory immunoglobulin a (sIgA)-binding nucleic acid molecule, sIgA analysis sensor, and sIgA analysis method
#68Read Through Of Truncated Proteins In Premature Termination Codon Diseases Using An Optimized Genetic Codon Expansion System
#69RNAi agents for inhibiting expression of alpha-ENaC and methods of use
#70Isolation of target nucleic acids
#71Argonaute protein-double stranded RNA complexes and uses related thereto
#72DNA aptamer that binds to vWF
#73PYRAZOLOTRIAZOLYL NUCLEOSIDE ANALOGUES AND OLIGONUCLEOTIDES COMPRISING THEM
#74Methods of enhancing translation ability of RNA molecules, treatments, and kits
#75Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
#76Method for generating aptamers with improved off-rates
#77Materials and methods for modulation of tendon healing
#78RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Neuromuscular Disorders
#79Guide RNA with chemical modifications
#80siRNA compounds comprising terminal substitutions
#81Organic compositions to treat HSF1-related diseases
#82Oligonucleotide comprising an inosine for treating DMD
#83APTAMERS FOR TOPICAL DELIVERY
#84Immunostimulatory sequence oligonucleotides and methods of using the same
#85System of interdependent anticancer antisense oligonucleotides targeting mRNAs the targets of which are NADPH-dependent, combined with one or more inhibitors of the Pentose Phosphate Pathway to deplete NADPH
#86Materials and methods for modulation of tendon healing
#87Guide RNA with chemical modifications
#88OLIGONUCLEOTIDE COMPRISING AN INOSINE FOR TREATING DMD
#89Genome editing using effector oligonucleotides for therapeutic treatment
#90ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES
#91Oligonucleotide comprising an inosine for treating DMD
#92Method for Generating Aptamers with Improved Off-Rates
#93Therapeutic oligonucleotides comprising pyrazolotriazine nucleotide analogues
#94siRNA compounds comprising terminal substitutions
#95RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
#96Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them
#97Immunostimulatory sequence oligonucleotides and methods of using the same
#98Methods and compositions for enhancing the efficacy and specificity of RNA silencing
#99Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction
#100Methods and compositions for enhancing the efficacy and specificity of RNA silencing
#101Immunostimulatory sequence oligonucleotides and methods of using the same
#102Sirna compounds comprising terminal substitutions
#103STRONGLY BOUND BASE-MODIFIED OLIGONUCLEOTIDES
#104OLIGONUCLEOTIDE COMPRISING AN INOSINE FOR TREATING DMD
#105Method for generating aptamers with improved off-rates
#106Allele-specific RNA interference
#107METHODS FOR INCREASING IN VIVO EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS
#108SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF
#109High potency siRNAS for reducing the expression of target genes
#110Synthetic RNA-based agonists of TLR7
#111Immunostimulatory sequence oligonucleotides and methods of using the same
#112Methods and compositions for enhancing the efficacy and specificity of RNA silencing
#113Methods and compositions for enhancing the efficacy and specificity of RNA silencing
#114Methods and compositions for enhancing the efficacy and specificity of RNA silencing
#1152-Azapurine compounds and their use
#1162' Deoxy-2'-Alkylnucleotide Containing Nucleic Acid
#1172'-Modified Oligonucleotides
#118Method for generating aptamers with improved off-rates
#1192'-MODIFIED OLIGONUCLEOTIDES
#120Transition state analog inhibitors of ricin A-chain
#121Antisense agents combining strongly bound base-modified oligonucleotide and artificial nuclease
#122Small interfering RNA specific to sub-units α, α′and β of the Kinase Protein ck2, and the applications of the same
#123RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA)
#124Immunopotentiator and method for enhancing immunoactivity using the same
#125Aptamer medicinal chemistry
#1262-azapurine compounds and their uses
#127Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
#128Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
#1292'-deoxy-2'alkylnucleotide containing nucleic acid
#130Allele-specific RNA interference
#131Immunostimulatory sequence oligonucleotides and methods of using the same
#132Oligomeric compounds having modified phosphate groups
#133RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
#134Methods and compositions for blocking progression of a disease state
#135Methods and compositions for enhancing the efficacy and specificity of RNA silencing
#136Polymearase III-based expression of therapeutic RNAs
#137Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation
#138Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation
#139Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
#140Triplex-forming oligonucleotides containing modified purines and their applications
#141Methods and compositions for modulating splicing